Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 614
- Registration Number
- NCT00664742
- Locations
- 🇹🇷
Götzepe Education and Research Hospital, Istanbul, Turkey
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
- Conditions
- Arthritis, Gouty
- Interventions
- Biological: canakinumabOther: placebo matching dexamethasoneOther: placebo matching canakinumab
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 6
- Registration Number
- NCT00663169
- Locations
- 🇬🇧
Novartis Investigator Site, Glasgow, United Kingdom
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 920
- Registration Number
- NCT00662649
- Locations
- 🇹🇷
Novartis Investigational Site, Yenisehir/Izmir, Turkey
🇮🇱Novaratis Investigative Site, Ashkelon, Israel
🇬🇧Novartis Investigative Site, Sheffield, United Kingdom
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00660309
- Locations
- 🇺🇸
Novartis Investigator Site, Boston, Massachusetts, United States
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 122
- Registration Number
- NCT00658320
- Locations
- 🇯🇵
Novartis Pharma K.K., Japan, Tokyo, Japan
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 328
- Registration Number
- NCT00654875
- Locations
- 🇪🇸
Investigative Site, Valencia, Spain
Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 63
- Registration Number
- NCT00651105
- Locations
- 🇩🇪
Novartis Investigator Site, Berlin, Germany
Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months
- Conditions
- Influenza
- Interventions
- Biological: Influenza Trivalent Inactivated vaccines NovartisBiological: Influenza Trivalent Inactivated vaccines
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 360
- Registration Number
- NCT00649883
- Locations
- 🇬🇹
Dr. Carlos Fernando Grazioso Aragón, Guatemala City, Guatemala
🇬🇹Centro Clínico La Quinta, Guatemala City, Guatemala
🇬🇹Clínicas Dr. Rafael Montiel, Guatemala City, Guatemala
Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00646737
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, Brazil
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 525
- Registration Number
- NCT00646542